美国胃肠病学会研究所技术综述:治疗药物监测在炎症性肠病管理中的作用
本技术综述按照GRADE框架制定,聚焦生物制剂(抗肿瘤坏死因子-α药物)和硫嘌呤类药物的治疗药物监测应用。探讨反应性监测与经验性调整、常规主动监测与不监测的获益与风险,以及用药前硫嘌呤甲基转移酶检测和不同谷浓度的效能,因数据缺乏未涉及维得利珠单抗或乌司奴单抗。
要点
- TDM基于药物暴露与结局相关及个体间药代/药效差异的前提。
- 综述聚焦抗TNF-α药物和硫嘌呤的反应性与主动TDM策略。
- 因数据缺乏,未涉及维得利珠单抗或乌司奴单抗的TDM。
核心结论
- TDM是优化炎症性肠病治疗的有前景策略,基于药物暴露与结局相关及药代/药效个体间差异的前提。
研究设计与样本
- 本技术综述按照GRADE框架制定,用于干预性和预后性研究,为美国胃肠病学会临床指南提供依据。
- 综述聚焦生物制剂(抗肿瘤坏死因子-α药物)和硫嘌呤类药物的TDM应用。
主要发现
- 综述探讨反应性TDM(活动性炎症性肠病患者)指导治疗调整与经验性治疗调整相比的获益与风险。
- 综述探讨常规主动TDM(疾病静止期患者常规临床 care中)与不常规TDM相比的获益与风险。
- 综述探讨启动硫嘌呤前常规检测硫嘌呤甲基转移酶活性或基因型与经验性按体重给药相比的获益与风险。
- 综述探索抗TNF药物和硫嘌呤不同谷浓度在反应性TDM临床决策中的效能。
局限性
- 因数据缺乏,本综述未涉及维得利珠单抗或乌司奴单抗等较新获批生物制剂的TDM作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic drug monitoring (TDM), which involves measurement of drug or active metabolite levels and anti-drug antibodies, is a promising strategy that can be used to optimize inflammatory bowel disease therapeutics. It is based on the premise that there is a relationship between drug exposure and outcomes, and that considerable inter-individual variability exists in how patients metabolize the drug (pharmacokinetics) and the magnitude and duration of response to therapy (pharmacodynamics). Therefore, the American Gastroenterological Association has prioritized clinical guidelines on the role of TDM in the management of inflammatory bowel disease. To inform these clinical guidelines, this technical review was developed in accordance with the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework for interventional and prognostic studies, and focused on the application of TDM for biologic therapy, specifically anti-tumor necrosis factor-α agents, and for thiopurines. Focused questions address the benefits and risks of a strategy of reactive TDM (in patients with active inflammatory bowel disease) to guide treatment changes compared with empiric treatment changes, and the benefits and risks of a strategy of routine proactive TDM (during routine clinical care in patients with quiescent disease) compared with no routine TDM. Additionally, the review addresses the benefits and risks of routine measurement of thiopurine methyltransferase enzyme activity or genotype before starting thiopurine therapy compared with empiric weight-based dosing and explores the performance of different trough drug concentrations for anti-tumor necrosis factor agents and thiopurines to inform clinical decision making when applying TDM in a reactive setting. Due to a paucity of data, this review does not address the role of TDM for more recently approved biologic agents, such as vedolizumab or ustekinumab.
引用
- Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017. PMID: 28774547. doi:10.1053/j.gastro.2017.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。